Table 1 Main characteristics of the study population (N = 68)a
Characteristics | Value |
|---|---|
Age, years, median (range) | 74 (44 to 99) |
Male/female gender, n (%) | 40 (58.9)/28 (41.1) |
Smoker, pack-years, median (range) | 50 (10 to 130) |
Ex-smoker, n (%) | 46 (67.6) |
Diuretic treatment more than four weeks, n (%) | 21 (30.9) |
Systemic corticosteroid treatment more than four weeks, n (%) | 5 (7.3) |
Home oxygen therapy, n (%) | 26 (38.2) |
Home noninvasive ventilation, n (%) | 6 (8.8) |
Body weight, kg, median (range) | 61.8 (34 to 142) |
FEV1, mL, median (range) | 800 (350 to 1940) |
FEV1/FVC, %, median (range) | 50.9 (24 to 66) |
LVEF, %, median (range) | 60 (20 to 80) |
SAPS II at ICU admission, median (range) | 47 (20 to 95) |
Lenght of ICU stay, days, median (range) | 21 (6 to 123) |
Length of invasive mechanical ventilation, days, median (range) | 18 (3 to 110) |
ICU mortality, n (%) | 16 (23.5) |
Cause of respiratory failure | |
Pneumonia, n (%) | 22 (32.4) |
Bronchitis, n (%) | 17 (25) |
Left ventricular failure, n (%) | 5 (7.3) |
Surgery, n (%) | 4 (5.9) |
Use of sedative drugs, n (%) | 6 (8.8) |
Pulmonary embolism, n (%) | 1 (1.5) |
Unknown, n (%) | 13 (19.1) |
Laboratory measurements before onset ACET administration | |
pH, median (range) | 7.45 (7.34 to 7.57) |
PaCO2, mmHg, median (range) | 55 (36 to 93) |
PaO2, mmHg, median (range) | 78 (41 to 136) |
Serum bicarbonate, mmol/L, median (range) | 37.5 (27 to 58) |
Serum potassium, mmol/L, median (range) | 3.8 (2.7 to 4.6) |
Serum chloride, mmol/L, median (range) | 96 (69 to 108) |
Serum protein, g/L, median (range) | 57 (40 to 72) |
Serum creatinine, μmol/L, median (range) | 64 (22 to 202) |
Additional treatments during ACET administration | |
Furosemide, n (%) | 32 (47.1) |
Systemic glucocorticoid, n (%) | 10 (14.7) |
β2-agonists, n (%) | 8 (11.7) |
Fluid load, mL, median (range) | 1, 000 (0 to 2, 300) |
Pressure-support ventilation, n (%) | 31 (45.6) |
Volume-assisted ventilation, n (%) | 37 (54.4) |